{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T02:33:45Z","timestamp":1770518025569,"version":"3.49.0"},"reference-count":127,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDD"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Pulmonary, nasal, and nose-to-brain diseases involve clinical approaches, such as bronchodilators,\ninhaled steroids, oxygen therapy, antibiotics, antihistamines, nasal steroids, decongestants,\nintranasal drug delivery, neurostimulation, and surgery to treat patients. However, systemic\nmedicines have serious adverse effects, necessitating the development of inhaled formulations that\nallow precise drug delivery to the airways with minimum systemic drug exposure. Particle size, surface\ncharge, biocompatibility, drug capacity, and mucoadhesive are unique chemical and physical\nfeatures that must be considered for pulmonary and nasal delivery routes due to anatomical and permeability\nconsiderations. The traditional management of numerous chronic diseases has a variety of\ndrawbacks. As a result, targeted medicine delivery systems that employ nanotechnology enhancer\ndrug efficiency and optimize the overall outcome are created. The pulmonary route is one of the\nmost essential targeted drug delivery systems because it allows the administering of drugs locally\nand systemically to the lungs, nasal cavity, and brain. Furthermore, the lungs' beneficial characteristics,\nsuch as their ability to inhibit first-pass metabolism and their thin epithelial layer, help treat\nseveral health complications. The potential to serve as noninvasive self-administration delivery sites\nof the lung and nasal routes is discussed in this script. New methods for treating respiratory and some\nsystemic diseases with inhalation have been explored and highlight particular attention to using specialized\nnanocarriers for delivering various drugs via the nasal and pulmonary pathways. The design\nand development of inhaled nanomedicine for pulmonary, nasal, and respiratory medicine applications\nis a potential approach for clinical translation.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0115672018268047231207105652","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T15:25:56Z","timestamp":1706196356000},"page":"3-14","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Recent Advancement in Inhaled Nano-drug Delivery for Pulmonary, Nasal, and Nose-to-brain Diseases"],"prefix":"10.2174","volume":"22","author":[{"given":"Qiuxia","family":"Fu","sequence":"first","affiliation":[{"name":"Department of General Medicine, Luzhou People's Hospital, Luzhou 646000, Sichuan, China, (PRC)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangjie","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Luzhou People's Hospital, Luzhou 646000, Sichuan, China, (PRC)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cao","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Luzhou People's Hospital, Luzhou 646000, Sichuan, China, (PRC)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias Achu","family":"Muluh","sequence":"additional","affiliation":[{"name":"Shenzhen University Medical School,\nShenzhen University, Shenzhen 518060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umer","family":"Anayyat","sequence":"additional","affiliation":[{"name":"Shenzhen University Medical School,\nShenzhen University, Shenzhen 518060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of\nPharmacy, Luzhou People's Hospital, Luzhou 646000, Sichuan, China PRC"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0025-7125(05)70603-9","volume":"82","author":"Feinerman C.E.","year":"1998","unstructured":"Feinerman C.E.; Pulmonary diseases in women. Med Clin North Am  1998,82(2),189-202","journal-title":"Med Clin North Am"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s00292-014-1924-0","volume":"35","author":"Hager T.","year":"2014","unstructured":"Hager T.; Reis H.; Theegarten D.; Infectious pulmonary diseases. Pathologe  2014,35(6),606-611","journal-title":"Pathologe"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/17425247.2022.2029845","volume":"19","year":"2022","unstructured":"P, A. Nose-to-brain drug delivery for the treatment of Alzheimer\u2019s disease: Current advancements and challenges. Expert Opin Drug Deliv  2022,19(1),87-102","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jconrel.2018.05.011","volume":"281","author":"Agrawal M.","year":"2018","unstructured":"Agrawal M.; Saraf S.; Saraf S.; Antimisiaris S.G.; Chougule M.B.; Shoyele S.A.; Alexander A.; Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Control Release  2018,281,139-177","journal-title":"J Control Release"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3390\/pharmaceutics12020138","volume":"12","author":"Giunchedi P.","year":"2020","unstructured":"Giunchedi P.; Gavini E.; Bonferoni M.C.; Nose-to-brain delivery. Pharmaceutics  2020,12(2),138","journal-title":"Pharmaceutics"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1124\/jpet.121.000530","volume":"378","author":"P\u00e9rez-Osorio I.N.","year":"2021","unstructured":"P\u00e9rez-Osorio I.N.; Espinosa A.; Giraldo Vel\u00e1zquez M.; Padilla P.; B\u00e1rcena B.; Fragoso G.; Jung-Cook H.; Besedovsky H.; Meneses G.; Sciutto Conde E.L.; Nose-to-brain delivery of dexamethasone: Biodistribution studies in mice. J Pharmacol Exp Ther  2021,378(3),244-250","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"583","DOI":"10.4155\/fmc-2023-0048","volume":"15","author":"Bhat A.A.","year":"2023","unstructured":"Bhat A.A.; Thapa R.; Goyal A.; Subramaniyan V.; Kumar D.; Gupta S.; Singh S.K.; Dua K.; Gupta G.; Curcumin-based nanoformulations as an emerging therapeutic strategy for inflammatory lung diseases. Future Med Chem  2023,15(7),583-586","journal-title":"Future Med Chem"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"144","DOI":"10.2174\/1567201819666220401091632","volume":"20","author":"Tanna V.","year":"2023","unstructured":"Tanna V.; Sawarkar S.P.; Ravikumar P.; Exploring nose to brain nano delivery for effective management of migraine. Curr Drug Deliv  2023,20(2),144-157","journal-title":"Curr Drug Deliv"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"116671","DOI":"10.1016\/j.lfs.2019.116671","volume":"233","author":"Arora S.","year":"2019","unstructured":"Arora S.; Ahmad S.; Irshad R.; Goyal Y.; Rafat S.; Siddiqui N.; Dev K.; Husain M.; Ali S.; Mohan A.; Syed M.A.; TLRs in pulmonary diseases. Life Sci  2019,233,116671","journal-title":"Life Sci"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.2217\/nnm.15.74","volume":"10","author":"Bosetti R.","year":"2015","unstructured":"Bosetti R.; Cost\u2013effectiveness of nanomedicine: The path to a future successful and dominant market? Nanomedicine  2015,10(12),1851-1853","journal-title":"Nanomedicine"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s00292-006-0823-4","volume":"27","author":"Brasch F.","year":"2006","unstructured":"Brasch F.; Interstitial pulmonary diseases. Pathologe  2006,27(2),116-132","journal-title":"Pathologe"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"170059","DOI":"10.1183\/16000617.0059-2017","volume":"26","author":"Harari S.","year":"2017","unstructured":"Harari S.; Humbert M.; Rare pulmonary diseases: A common fight. Eur Respir Rev  2017,26(145),170059","journal-title":"Eur Respir Rev"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"e1586","DOI":"10.1002\/wnan.1586","volume":"12","author":"Anderson C.F.","year":"2020","unstructured":"Anderson C.F.; Grimmett M.E.; Domalewski C.J.; Cui H.; Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol  2020,12(1),e1586","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.2147\/IJN.S295300","volume":"16","author":"Muluh T.A.","year":"2021","unstructured":"Muluh T.A.; Chen Z.; Li Y.; Xiong K.; Jin J.; Fu S.; Wu J.; Enhancing cancer immunotherapy treatment goals by using nanoparticle delivery system. Int J Nanomedicine  2021,16,2389-2404","journal-title":"Int J Nanomedicine"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","volume":"22","author":"Banwell B.","year":"2023","unstructured":"Banwell B.; Bennett J.L.; Marignier R.; Kim H.J.; Brilot F.; Flanagan E.P.; Ramanathan S.; Waters P.; Tenembaum S.; Graves J.S.; Chitnis T.; Brandt A.U.; Hemingway C.; Neuteboom R.; Pandit L.; Reindl M.; Saiz A.; Sato D.K.; Rostasy K.; Paul F.; Pittock S.J.; Fujihara K.; Palace J.; Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD panel proposed criteria. Lancet Neurol  2023,22(3),268-282","journal-title":"Lancet Neurol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1042986","DOI":"10.3389\/fbioe.2022.1042986","volume":"10","author":"Cao Y.","year":"2022","unstructured":"Cao Y.; Zhang R.; The application of nanotechnology in treatment of Alzheimer\u2019s disease. Front Bioeng Biotechnol  2022,10,1042986","journal-title":"Front Bioeng Biotechnol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"e29059","DOI":"10.7759\/cureus.29059","volume":"14","author":"Kher C.","year":"2022","unstructured":"Kher C.; Kumar S.; The application of nanotechnology and nanomaterials in cancer diagnosis and treatment: A review. Cureus  2022,14(9),e29059","journal-title":"Cureus"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"100047","DOI":"10.1016\/j.bbiosy.2022.100047","volume":"6","author":"Tillman L.","year":"2022","unstructured":"Tillman L.; Tabish T.A.; Kamaly N.; Moss P.; El-briri A.; Thiemermann C.; Pranjol M.Z.I.; Yaqoob M.M.; Advancements in nanomedicines for the detection and treatment of diabetic kidney disease. Biomaterials and Biosystems  2022,6,100047","journal-title":"Biomaterials and Biosystems"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11095-020-02786-z","volume":"37","author":"Gon\u00e7alves J.","year":"2020","unstructured":"Gon\u00e7alves J.; Alves G.; Carona A.; Bicker J.; Vitorino C.; Falc\u00e3o A.; Fortuna A.; Pre-clinical assessment of the nose-to-brain delivery of zonisamide after intranasal administration. Pharm Res  2020,37(4),74","journal-title":"Pharm Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1037741","DOI":"10.3389\/fcvm.2022.1037741","volume":"9","author":"Gong Y.","year":"2023","unstructured":"Gong Y.; Liu H.; Ke S.; Zhuo L.; Wang H.; Latest advances in biomimetic nanomaterials for diagnosis and treatment of cardiovascular disease. Front Cardiovasc Med  2023,9,1037741","journal-title":"Front Cardiovasc Med"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.3390\/life12122078","volume":"12","author":"Debele T.A.","year":"2022","unstructured":"Debele T.A.; Park Y.; Application of nanoparticles: diagnosis, therapeutics, and delivery of insulin\/anti-diabetic drugs to enhance the therapeutic efficacy of diabetes mellitus. Life  2022,12(12),2078","journal-title":"Life"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1021\/acsnano.6b08551","volume":"11","author":"Miller M.R.","year":"2017","unstructured":"Miller M.R.; Raftis J.B.; Langrish J.P.; McLean S.G.; Samutrtai P.; Connell S.P.; Wilson S.; Vesey A.T.; Fokkens P.H.B.; Boere A.J.F.; Krystek P.; Campbell C.J.; Hadoke P.W.F.; Donaldson K.; Cassee F.R.; Newby D.E.; Duffin R.; Mills N.L.; Inhaled nanoparticles accumulate at sites of vascular disease. ACS Nano  2017,11(5),4542-4552","journal-title":"ACS Nano"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/08958370902962283","volume":"21","author":"Bur M.","year":"2009","unstructured":"Bur M.; Henning A.; Hein S.; Schneider M.; Lehr C.M.; Inhalative nanomedicine\u2014Opportunities and challenges. Inhal Toxicol  2009,21(sup1)(Suppl. 1),137-143","journal-title":"Inhal Toxicol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.3889\/oamjms.2019.559","volume":"7","author":"Chinnasamy V.","year":"2019","unstructured":"Chinnasamy V.; Subramaniyan V.; Chandiran S.; Kayarohanam S.; Kanniyan D.C.; Velaga V.S.S.R.; Muhammad S.; Antiarthritic activity of achyranthes aspera on formaldehyde - induced arthritis in rats. Open Access Maced J Med Sci  2019,7(17),2709-2714","journal-title":"Open Access Maced J Med Sci"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41565-020-00810-2","volume":"16","author":"Cifuentes-Rius A.","year":"2021","unstructured":"Cifuentes-Rius A.; Desai A.; Yuen D.; Johnston A.P.R.; Voelcker N.H.; Inducing immune tolerance with dendritic cell-targeting nanomedicines. Nat Nanotechnol  2021,16(1),37-46","journal-title":"Nat Nanotechnol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2147\/IJN.S596","volume":"3","author":"de Jong W.H.","year":"2008","unstructured":"de Jong W.H.; Borm P.J.; Drug delivery and nanoparticles: Applications and hazards. Int J Nanomedicine  2008,3(2),133-149","journal-title":"Int J Nanomedicine"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.jconrel.2020.11.005","volume":"330","author":"Ding L.","year":"2021","unstructured":"Ding L.; Tang S.; Wyatt T.A.; Knoell D.L.; Oupick\u00fd D.; Pulmonary siRNA delivery for lung disease: Review of recent progress and challenges. J Control Release  2021,330,977-991","journal-title":"J Control Release"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"233","DOI":"10.5858\/arpa.2020-0543-RA","volume":"146","author":"Rosen Y.","year":"2022","unstructured":"Rosen Y.; Pathology of granulomatous pulmonary diseases. Arch Pathol Lab Med  2022,146(2),233-251","journal-title":"Arch Pathol Lab Med"},{"key":"ref=29","first-page":"6133","volume":"10","author":"Albini A.","year":"2015","unstructured":"Albini A.; Pagani A.; Pulze L.; Bruno A.; Principi E.; Congiu T.; Gini E.; Grimaldi A.; Bassani B.; De Flora S.; de Eguileor M.; Noonan D.M.; Environmental impact of multi-wall carbon nanotubes in a novel model of exposure: Systemic distribution, macrophage accumulation, and amyloid deposition. Int J Nanomedicine  2015,10,6133-6145","journal-title":"Int J Nanomedicine"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.3390\/antiox9111075","volume":"9","author":"Fuloria S.","year":"2020","unstructured":"Fuloria S.; Subramaniyan V.; Karupiah S.; Kumari U.; Sathasivam K.; Meenakshi D.U.; Wu Y.S.; Guad R.M.; Udupa K.; Fuloria N.K.; A comprehensive review on source, types, effects, nanotechnology, detection, and therapeutic management of reactive carbonyl species associated with various chronic diseases. Antioxidants  2020,9(11),1075","journal-title":"Antioxidants"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijbiomac.2021.10.113","volume":"193","author":"Wen Q.","year":"2021","unstructured":"Wen Q.; Erythrocyte membrane-camouflaged gefitinib\/albumin nanoparticles for tumor imaging and targeted therapy against lung cancer. Int J Biol Macromol  2021,193((Pt A):),228-237","journal-title":"Int J Biol Macromol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1161\/CIRCULATIONAHA.106.685206","volume":"116","author":"Han M.K.","year":"2007","unstructured":"Han M.K.; McLaughlin V.V.; Criner G.J.; Martinez F.J.; Pulmonary diseases and the heart. Circulation  2007,116(25),2992-3005","journal-title":"Circulation"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.resinv.2020.07.002","volume":"59","author":"Tamura G.","year":"2021","unstructured":"Tamura G.; Choi J.W.; Takeda S.; Nishina N.; Hayashi A.; Aerosol velocity of two pressurized metered-dose inhalers using AEROSPHERE\u00ae delivery technology. Respir Investig  2021,59(1),153-154","journal-title":"Respir Investig"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"596","DOI":"10.3390\/life12040596","volume":"12","author":"Ahmad A.","year":"2022","unstructured":"Ahmad A.; Pharmacological strategies and recent advancement in nano-drug delivery for targeting asthma. Life  2022,12(4),596","journal-title":"Life"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"121720","DOI":"10.1016\/j.ijpharm.2022.121720","volume":"620","author":"Cunha S.","year":"2022","unstructured":"Cunha S.; Swedrowska M.; Bellahnid Y.; Xu Z.; Sousa Lobo J.M.; Forbes B.; Silva A.C.; Thermosensitive in situ hydrogels of rivastigmine-loaded lipid-based nanosystems for nose-to-brain delivery: Characterisation, biocompatibility, and drug deposition studies. Int J Pharm  2022,620,121720","journal-title":"Int J Pharm"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"105632","DOI":"10.1016\/j.ejps.2020.105632","volume":"157","author":"Gon\u00e7alves J.","year":"2021","unstructured":"Gon\u00e7alves J.; Alves G.; Fonseca C.; Carona A.; Bicker J.; Falc\u00e3o A.; Fortuna A.; Is intranasal administration an opportunity for direct brain delivery of lacosamide? Eur J Pharm Sci  2021,157,105632","journal-title":"Eur J Pharm Sci"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.nano.2015.01.007","volume":"11","author":"Muralidharan P.","year":"2015","unstructured":"Muralidharan P.; Malapit M.; Mallory E.; Hayes D.; Mansour H.M.; Inhalable nanoparticulate powders for respiratory delivery. Nanomedicine  2015,11(5),1189-1199","journal-title":"Nanomedicine"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"E460","DOI":"10.1503\/cmaj.211747","volume":"194","author":"Fidler L.","year":"2022","unstructured":"Fidler L.; Green S.; Wintemute K.; Pressurized metered-dose inhalers and their impact on climate change. CMAJ  2022,194(12),E460","journal-title":"CMAJ"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"995","DOI":"10.2174\/1389450120666190307101642","volume":"20","author":"Mohsen A.M.","year":"2019","unstructured":"Mohsen A.M.; Nanotechnology advanced strategies for the management of diabetes mellitus. Curr Drug Targets  2019,20(10),995-1007","journal-title":"Curr Drug Targets"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.rmr.2018.02.001","volume":"35","author":"Rosi\u00e8re R.","year":"2018","unstructured":"Rosi\u00e8re R.; Hureaux J.; Levet V.; Amighi K.; Wauthoz N.; Inhaled chemotherapy - Part 1: General concept and current technological challenges. Rev Mal Respir  2018,35(4),357-377","journal-title":"Rev Mal Respir"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/02770903.2020.1731823","volume":"58","author":"Topal E.","year":"2021","unstructured":"Topal E.; Arga M.; \u00d6zmen A.H.; Kur\u015fun M.A.; \u0130lhan \u00d6.A.; Al\u0131c\u0131 M.; The pharmacists\u2019 ability to use pressurized metered-dose inhalers with a spacer device and factors affecting it. J Asthma  2021,58(5),659-664","journal-title":"J Asthma"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1208\/s12249-020-01782-1","volume":"21","author":"Wang W.","year":"2020","unstructured":"Wang W.; Huang Z.; Xue K.; Li J.; Wang W.; Ma J.; Ma C.; Bai X.; Huang Y.; Pan X.; Wu C.; Development of aggregation-caused quenching probe-loaded pressurized metered-dose inhalers with fluorescence tracking potentials. AAPS PharmSciTech  2020,21(8),296","journal-title":"AAPS PharmSciTech"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.2147\/COPD.S252435","volume":"15","author":"Barjaktarevic I.Z.","year":"2020","unstructured":"Barjaktarevic I.Z.; Milstone A.P.; Nebulized therapies in copd: past, present, and the future. Int J Chron Obstruct Pulmon Dis  2020,15,1665-1677","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.semcancer.2022.01.007","volume":"86","author":"Li X.","year":"2022","unstructured":"Li X.; Chen L.; Luan S.; Zhou J.; Xiao X.; Yang Y.; Mao C.; Fang P.; Chen L.; Zeng X.; Gao H.; Yuan Y.; The development and progress of nanomedicine for esophageal cancer diagnosis and treatment. Semin Cancer Biol  2022,86(Pt 2),873-885","journal-title":"Semin Cancer Biol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2217\/nnm-2022-0179","volume":"18","author":"Urso A.","year":"2023","unstructured":"Urso A.; Meloni F.; Malatesta M.; Latorre R.; Damoci C.; Crapanzano J.; Pandolfi L.; Giustra M.D.; Pearson M.; Colombo M.; Schilling K.; Glabonjat R.A.; D\u2019Ovidio F.; Endotracheal nebulization of gold nanoparticles for noninvasive pulmonary drug delivery. Nanomedicine  2023,18(4),317-330","journal-title":"Nanomedicine"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"e1697","DOI":"10.1002\/wnan.1697","volume":"13","author":"Liu M.","year":"2021","unstructured":"Liu M.; Li L.; Jin D.; Liu Y.; Nanobody\u2014A versatile tool for cancer diagnosis and therapeutics. Wiley Interdiscip Rev Nanomed Nanobiotechnol  2021,13(4),e1697","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1021\/acsnano.8b05136","volume":"13","author":"Li X.","year":"2019","unstructured":"Li X.; Bottini M.; Zhang L.; Zhang S.; Chen J.; Zhang T.; Liu L.; Rosato N.; Ma X.; Shi X.; Wu Y.; Guo W.; Liang X.J.; Core\u2013satellite nanomedicines for in vivo real-time monitoring of enzyme-activatable drug release by fluorescence and photoacoustic dual-modal imaging. ACS Nano  2019,13(1),176-186","journal-title":"ACS Nano"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1900419","DOI":"10.1183\/13993003.00419-2019","volume":"55","author":"Lin V.Y.","year":"2020","unstructured":"Lin V.Y.; Kaza N.; Birket S.E.; Kim H.; Edwards L.J.; LaFontaine J.; Liu L.; Mazur M.; Byzek S.A.; Hanes J.; Tearney G.J.; Raju S.V.; Rowe S.M.; Excess mucus viscosity and airway dehydration impact COPD airway clearance. Eur Respir J  2020,55(1),1900419","journal-title":"Eur Respir J"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejpb.2017.12.017","volume":"124","author":"Nafee N.","year":"2018","unstructured":"Nafee N.; Forier K.; Braeckmans K.; Schneider M.; Mucus-penetrating solid lipid nanoparticles for the treatment of cystic fibrosis: Proof of concept, challenges and pitfalls. Eur J Pharm Biopharm  2018,124,125-137","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"2000673","DOI":"10.1002\/smll.202000673","volume":"16","author":"Liu X.","year":"2020","unstructured":"Liu X.; Tang I.; Wainberg Z.A.; Meng H.; Safety considerations of cancer nanomedicine\u2014a key step toward translation. Small  2020,16(36),2000673","journal-title":"Small"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jconrel.2018.07.001","volume":"285","author":"Osman G.","year":"2018","unstructured":"Osman G.; Rodriguez J.; Chan S.Y.; Chisholm J.; Duncan G.; Kim N.; Tatler A.L.; Shakesheff K.M.; Hanes J.; Suk J.S.; Dixon J.E.; PEGylated enhanced cell penetrating peptide nanoparticles for lung gene therapy. J Control Release  2018,285,35-45","journal-title":"J Control Release"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.2147\/IJN.S300991","volume":"16","author":"Malviya R.","year":"2021","unstructured":"Malviya R.; Raj S.; Fuloria S.; Subramaniyan V.; Sathasivam K.; Kumari U.; Unnikrishnan Meenakshi D.; Porwal O.; Hari Kumar D.; Singh A.; Chakravarthi S.; Kumar Fuloria N.; Evaluation of antitumor efficacy of chitosan-tamarind gum polysaccharide polyelectrolyte complex stabilized nanoparticles of simvastatin. Int J Nanomedicine  2021,16,2533-2553","journal-title":"Int J Nanomedicine"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"e0202456","DOI":"10.1371\/journal.pone.0202456","volume":"14","author":"Paris A.J.","year":"2019","unstructured":"Paris A.J.; Guo L.; Dai N.; Katzen J.B.; Patel P.N.; Worthen G.S.; Brenner J.S.; Using selective lung injury to improve murine models of spatially heterogeneous lung diseases. PLoS One  2019,14(4),e0202456","journal-title":"PLoS One"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"106079","DOI":"10.1016\/j.cmpb.2021.106079","volume":"204","author":"Talaat M.","year":"2021","unstructured":"Talaat M.; Si X.A.; Dong H.; Xi J.; Leveraging statistical shape modeling in computational respiratory dynamics: Nanomedicine delivery in remodeled airways. Comput Methods Programs Biomed  2021,204,106079","journal-title":"Comput Methods Programs Biomed"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"119969","DOI":"10.1016\/j.lfs.2021.119969","volume":"285","author":"Gulati N.","year":"2021","unstructured":"Gulati N.; Chellappan D.K.; MacLoughlin R.; Dua K.; Dureja H.; Inhaled nano-based therapeutics for inflammatory lung diseases: Recent advances and future prospects. Life Sci  2021,285,119969","journal-title":"Life Sci"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1039\/D1SM01206A","volume":"18","author":"Shimosaraya N.","year":"2021","unstructured":"Shimosaraya N.; Sotani T.; Miyagi Y.; Mondarte E.A.Q.; Suthiwanich K.; Hayashi T.; Nagata Y.; Sogawa H.; Sanda F.; Tyrosine-based photoluminescent diketopiperazine supramolecular aggregates. Soft Matter  2021,18(1),137-145","journal-title":"Soft Matter"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"8107","DOI":"10.1021\/acs.jpcb.1c03515","volume":"125","author":"Zhang Z.","year":"2021","unstructured":"Zhang Z.; Conant C.R.; El-Baba T.J.; Raab S.A.; Fuller D.R.; Hales D.A.; Clemmer D.E.; Diketopiperazine formation from fpgn k (n = 1\u20139) peptides: Rates of structural rearrangements and mechanisms. J Phys Chem B  2021,125(29),8107-8116","journal-title":"J Phys Chem B"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/j.ymthe.2017.03.011","volume":"25","author":"Mirshafiee V.","year":"2017","unstructured":"Mirshafiee V.; Jiang W.; Sun B.; Wang X.; Xia T.; Facilitating translational nanomedicine via predictive safety assessment. Mol Ther  2017,25(7),1522-1530","journal-title":"Mol Ther"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/978-0-387-73657-0_93","volume":"611","author":"Deppermann N.","year":"2009","unstructured":"Deppermann N.; Maison W.; Proline-based diketopiperazine-scaffolds. Adv Exp Med Biol  2009,611,203-204","journal-title":"Adv Exp Med Biol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"eaay9040","DOI":"10.1126\/science.aay9040","volume":"375","author":"Crosby D.","year":"2022","unstructured":"Crosby D.; Bhatia S.; Brindle K.M.; Coussens L.M.; Dive C.; Emberton M.; Esener S.; Fitzgerald R.C.; Gambhir S.S.; Kuhn P.; Rebbeck T.R.; Balasubramanian S.; Early detection of cancer. Science  2022,375(6586),eaay9040","journal-title":"Science"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.coph.2020.11.002","volume":"56","author":"Doroudian M.","year":"2021","unstructured":"Doroudian M.; O\u2019 Neill A.; Mac Loughlin R.; Prina-Mello A.; Volkov Y.; Donnelly S.C.; Nanotechnology in pulmonary medicine. Curr Opin Pharmacol  2021,56,85-92","journal-title":"Curr Opin Pharmacol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"5726","DOI":"10.1002\/jmv.27181","volume":"93","author":"Singh Y.","year":"2021","unstructured":"Singh Y.; Fuloria N.K.; Fuloria S.; Subramaniyan V.; Meenakshi D.U.; Chakravarthi S.; Kumari U.; Joshi N.; Gupta G.; N\u2010terminal domain of SARS CoV\u20102 spike protein mutation associated reduction in effectivity of neutralizing antibody with vaccinated individuals. J Med Virol  2021,93(10),5726-5728","journal-title":"J Med Virol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.3390\/pharmaceutics14122788","volume":"14","author":"Bhat A.A.","year":"2022","unstructured":"Bhat A.A.; Gupta G.; Alharbi K.S.; Afzal O.; Altamimi A.S.A.; Almalki W.H.; Kazmi I.; Al-Abbasi F.A.; Alzarea S.I.; Chellappan D.K.; Singh S.K.; MacLoughlin R.; Oliver B.G.; Dua K.; Polysaccharide-based nanomedicines targeting lung cancer. Pharmaceutics  2022,14(12),2788","journal-title":"Pharmaceutics"},{"key":"ref=64","first-page":"140","volume":"7","author":"Carrasco-Esteban E.","year":"2021","unstructured":"Carrasco-Esteban E.; Dom\u00ednguez-Rull\u00e1n J.A.; Barrionuevo-Castillo P.; Pelari-Mici L.; Leaman O.; Sastre-Gallego S.; L\u00f3pez-Campos F.; Current role of nanoparticles in the treatment of lung cancer. J Clin Transl Res  2021,7(2),140-155","journal-title":"J Clin Transl Res"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"015001","DOI":"10.1289\/EHP9086","volume":"130","author":"Sripada K.","year":"2022","unstructured":"Sripada K.; Wierzbicka A.; Abass K.; Grimalt J.O.; Erbe A.; R\u00f6llin H.B.; Weihe P.; D\u00edaz G.J.; Singh R.R.; Visnes T.; Rautio A.; Odland J.\u00d8.; Wagner M.; a children\u2019s health perspective on nano- and microplastics. Environ Health Perspect  2022,130(1),015001","journal-title":"Environ Health Perspect"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1144653","DOI":"10.3389\/fbioe.2023.1144653","volume":"11","author":"Doroudian M.","year":"2023","unstructured":"Doroudian M.; Zanganeh S.; Abbasgholinejad E.; Donnelly S.C.; Nanomedicine in lung cancer immunotherapy. Front Bioeng Biotechnol  2023,11,1144653","journal-title":"Front Bioeng Biotechnol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.3390\/ijms23031853","volume":"23","author":"Haider M.","year":"2022","unstructured":"Haider M.; Elsherbeny A.; Pittal\u00e0 V.; Consoli V.; Alghamdi M.A.; Hussain Z.; Khoder G.; Greish K.; Nanomedicine strategies for management of drug resistance in lung cancer. Int J Mol Sci  2022,23(3),1853","journal-title":"Int J Mol Sci"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"7072","DOI":"10.7150\/thno.57803","volume":"11","author":"Hsieh C.H.","year":"2021","unstructured":"Hsieh C.H.; Hsieh H.C.; Shih F.H.; Wang P.W.; Yang L.X.; Shieh D.B.; Wang Y.C.; An innovative NRF2 nano-modulator induces lung cancer ferroptosis and elicits an immunostimulatory tumor microenvironment. Theranostics  2021,11(14),7072-7091","journal-title":"Theranostics"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","volume":"34","author":"Jov\u010devska I.","year":"2020","unstructured":"Jov\u010devska I.; Muyldermans S.; The therapeutic potential of nanobodies. BioDrugs  2020,34(1),11-26","journal-title":"BioDrugs"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"e34245","DOI":"10.7759\/cureus.34245","volume":"15","author":"Koutu V.","year":"2023","unstructured":"Koutu V.; Gupta M.; Das S.; Rawat D.K.; Kharade V.; Pasricha R.K.; Nanotechnology in lung cancer therapeutics: A narrative review. Cureus  2023,15(1),e34245","journal-title":"Cureus"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","volume":"22","author":"Lahiri A.","year":"2023","unstructured":"Lahiri A.; Maji A.; Potdar P.D.; Singh N.; Parikh P.; Bisht B.; Mukherjee A.; Paul M.K.; Lung cancer immunotherapy: Progress, pitfalls, and promises. Mol Cancer  2023,22(1),40","journal-title":"Mol Cancer"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1038\/s41401-020-00594-0","volume":"42","author":"Miao Y.","year":"2021","unstructured":"Miao Y.; Chen M.; Zhou X.; Guo L.; Zhu J.; Wang R.; Zhang X.; Gan Y.; Chitosan oligosaccharide modified liposomes enhance lung cancer delivery of paclitaxel. Acta Pharmacol Sin  2021,42(10),1714-1722","journal-title":"Acta Pharmacol Sin"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"113918","DOI":"10.1016\/j.addr.2021.113918","volume":"178","author":"Raguraman R.","year":"2021","unstructured":"Raguraman R.; Srivastava A.; Munshi A.; Ramesh R.; Therapeutic approaches targeting molecular signaling pathways common to diabetes, lung diseases and cancer. Adv Drug Deliv Rev  2021,178,113918","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/3687700","volume":"2021","author":"Sharifi-Rad J.","year":"2021","unstructured":"Sharifi-Rad J.; Quispe C.; Patra J.K.; Singh Y.D.; Panda M.K.; Das G.; Adetunji C.O.; Michael O.S.; Sytar O.; Polito L.; \u017divkovi\u0107 J.; Cruz-Martins N.; Klimek-Szczykutowicz M.; Ekiert H.; Choudhary M.I.; Ayatollahi S.A.; Tynybekov B.; Kobarfard F.; Muntean A.C.; Grozea I.; Da\u015ftan S.D.; Butnariu M.; Szopa A.; Calina D.; Paclitaxel: Application in modern oncology and nanomedicine-based cancer therapy. Oxid Med Cell Longev  2021,2021,1-24","journal-title":"Oxid Med Cell Longev"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1021\/acsomega.2c04078","volume":"8","author":"Sharma A.","year":"2023","unstructured":"Sharma A.; Shambhwani D.; Pandey S.; Singh J.; Lalhlenmawia H.; Kumarasamy M.; Singh S.K.; Chellappan D.K.; Gupta G.; Prasher P.; Dua K.; Kumar D.; Advances in lung cancer treatment using nanomedicines. ACS Omega  2023,8(1),10-41","journal-title":"ACS Omega"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.semcancer.2019.08.017","volume":"69","author":"Tarasov V.V.","year":"2021","unstructured":"Tarasov V.V.; Svistunov A.A.; Chubarev V.N.; Dostdar S.A.; Sokolov A.V.; Brzecka A.; Sukocheva O.; Neganova M.E.; Klochkov S.G.; Somasundaram S.G.; Kirkland C.E.; Aliev G.; Extracellular vesicles in cancer nanomedicine. Semin Cancer Biol  2021,69,212-225","journal-title":"Semin Cancer Biol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.2217\/nnm-2021-0470","volume":"17","year":"2022","unstructured":"Vikas; Sahu, H.K.; Mehata, A.K.; Viswanadh, M.K.; Priya, V.; Muthu, M.S. Dual-receptor-targeted nanomedicines: Emerging trends and advances in lung cancer therapeutics. Nanomedicine  2022,17(19),1375-1395","journal-title":"Nanomedicine"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.semcancer.2020.02.009","volume":"69","author":"Woodman C.","year":"2021","unstructured":"Woodman C.; Vundu G.; George A.; Wilson C.M.; Applications and strategies in nanodiagnosis and nanotherapy in lung cancer. Semin Cancer Biol  2021,69,349-364","journal-title":"Semin Cancer Biol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1124\/pharmrev.120.000108","volume":"74","author":"Anderson S.","year":"2022","unstructured":"Anderson S.; Atkins P.; B\u00e4ckman P.; Cipolla D.; Clark A.; Daviskas E.; Disse B.; Entcheva-Dimitrov P.; Fuller R.; Gonda I.; Lundb\u00e4ck H.; Olsson B.; Weers J.; Inhaled medicines: Past, present, and future. Pharmacol Rev  2022,74(1),48-118","journal-title":"Pharmacol Rev"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"eabn7162","DOI":"10.1126\/sciadv.abn7162","volume":"8","author":"Bai X.","year":"2022","unstructured":"Bai X.; Zhao G.; Chen Q.; Li Z.; Gao M.; Ho W.; Xu X.; Zhang X.Q.; Inhaled siRNA nanoparticles targeting IL11 inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge. Sci Adv  2022,8(25),eabn7162","journal-title":"Sci Adv"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jconrel.2021.11.043","volume":"341","author":"Hope A.","year":"2022","unstructured":"Hope A.; Wade S.J.; Aghmesheh M.; Vine K.L.; Localized delivery of immunotherapy via implantable scaffolds for breast cancer treatment. J Control Release  2022,341,399-413","journal-title":"J Control Release"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"5852","DOI":"10.3390\/ijms15045852","volume":"15","author":"Paranjpe M.","year":"2014","unstructured":"Paranjpe M.; M\u00fcller-Goymann C.; Nanoparticle-mediated pulmonary drug delivery: A review. Int J Mol Sci  2014,15(4),5852-5873","journal-title":"Int J Mol Sci"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ijpharm.2013.02.035","volume":"447","author":"Trapani A.","year":"2013","unstructured":"Trapani A.; Di Gioia S.; Ditaranto N.; Cioffi N.; Goycoolea F.M.; Carbone A.; Garcia-Fuentes M.; Conese M.; Alonso M.J.; Systemic heparin delivery by the pulmonary route using chitosan and glycol chitosan nanoparticles. Int J Pharm  2013,447(1-2),115-123","journal-title":"Int J Pharm"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ijpharm.2013.04.077","volume":"451","author":"Yang L.","year":"2013","unstructured":"Yang L.; Luo J.; Shi S.; Zhang Q.; Sun X.; Zhang Z.; Gong T.; Development of a pulmonary peptide delivery system using porous nanoparticle-aggregate particles for systemic application. Int J Pharm  2013,451(1-2),104-111","journal-title":"Int J Pharm"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3390\/cancers11091383","volume":"11","author":"Karsch-Bluman A.","year":"2019","unstructured":"Karsch-Bluman A.; Avraham S.; Assayag M.; Schwob O.; Benny O.; Encapsulated carbenoxolone reduces lung metastases. Cancers  2019,11(9),1383","journal-title":"Cancers"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s42003-019-0337-2","volume":"2","author":"Marchetti G.M.","year":"2019","unstructured":"Marchetti G.M.; Burwell T.J.; Peterson N.C.; Cann J.A.; Hanna R.N.; Li Q.; Ongstad E.L.; Boyd J.T.; Kennedy M.A.; Zhao W.; Rickert K.W.; Grimsby J.S.; Dall\u2019Acqua W.F.; Wu H.; Tsui P.; Borrok M.J.; Gupta R.; Targeted drug delivery via caveolae-associated protein PV1 improves lung fibrosis. Commun Biol  2019,2(1),92","journal-title":"Commun Biol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"162","DOI":"10.2174\/1568009618666180525083451","volume":"19","author":"Islam N.","year":"2019","unstructured":"Islam N.; Richard D.; Inhaled micro\/nanoparticulate anticancer drug formulations: An emerging targeted drug delivery strategy for lung cancers. Curr Cancer Drug Targets  2019,19(3),162-178","journal-title":"Curr Cancer Drug Targets"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1039\/C9NR09011H","volume":"12","author":"Nie H.","year":"2020","unstructured":"Nie H.; Xie X.; Zhang D.; Zhou Y.; Li B.; Li F.; Li F.; Cheng Y.; Mei H.; Meng H.; Jia L.; Use of lung-specific exosomes for miRNA-126 delivery in non-small cell lung cancer. Nanoscale  2020,12(2),877-887","journal-title":"Nanoscale"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"2007557","DOI":"10.1002\/adma.202007557","volume":"33","author":"Jin Q.","year":"2021","unstructured":"Jin Q.; Zhu W.; Zhu J.; Zhu J.; Shen J.; Liu Z.; Yang Y.; Chen Q.; Nanoparticle\u2010mediated delivery of inhaled immunotherapeutics for treating lung metastasis. Adv Mater  2021,33(7),2007557","journal-title":"Adv Mater"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"411","DOI":"10.7150\/thno.33482","volume":"10","author":"Zhang K.","year":"2020","unstructured":"Zhang K.; Dong C.; Chen M.; Yang T.; Wang X.; Gao Y.; Wang L.; Wen Y.; Chen G.; Wang X.; Yu X.; Zhang Y.; Wang P.; Shang M.; Han K.; Zhou Y.; Extracellular vesicle-mediated delivery of miR-101 inhibits lung metastasis in osteosarcoma. Theranostics  2020,10(1),411-425","journal-title":"Theranostics"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2174\/1568009623666221020104603","volume":"23","author":"Muluh T.A.","year":"2023","unstructured":"Muluh T.A.; Lu X.; Zhang Y.; Li Y.; Fu Q.; Han Z.; Wang D.; Umar Shinge S.A.; Combined immunotherapy and targeted therapies for cancer treatment: Recent advances and future perspectives. Curr Cancer Drug Targets  2023,23(4),251-264","journal-title":"Curr Cancer Drug Targets"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.3390\/molecules27113490","volume":"27","author":"Agnihotri V.","year":"2022","unstructured":"Agnihotri V.; Agrawal Y.; Goyal S.; Sharma C.; Ojha S.; An update on advancements and challenges in inhalational drug delivery for pulmonary arterial hypertension. Molecules  2022,27(11),3490","journal-title":"Molecules"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1517\/17425247.2015.993968","volume":"12","author":"Ali M.E.","year":"2015","unstructured":"Ali M.E.; McConville J.T.; Lamprecht A.; Pulmonary delivery of anti-inflammatory agents. Expert Opin Drug Deliv  2015,12(6),929-945","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jconrel.2017.11.036","volume":"269","author":"Abdelaziz H.M.","year":"2018","unstructured":"Abdelaziz H.M.; Gaber M.; Abd-Elwakil M.M.; Mabrouk M.T.; Elgohary M.M.; Kamel N.M.; Kabary D.M.; Freag M.S.; Samaha M.W.; Mortada S.M.; Elkhodairy K.A.; Fang J.Y.; Elzoghby A.O.; Inhalable particulate drug delivery systems for lung cancer therapy: Nanoparticles, microparticles, nanocomposites and nanoaggregates. J Control Release  2018,269,374-392","journal-title":"J Control Release"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ijpharm.2008.09.017","volume":"367","author":"Beck-Broichsitter M.","year":"2009","unstructured":"Beck-Broichsitter M.; Gauss J.; Packhaeuser C.B.; Lahnstein K.; Schmehl T.; Seeger W.; Kissel T.; Gessler T.; Pulmonary drug delivery with aerosolizable nanoparticles in an ex vivo lung model. Int J Pharm  2009,367(1-2),169-178","journal-title":"Int J Pharm"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1080\/10717544.2017.1365395","volume":"24","author":"Chen R.","year":"2017","unstructured":"Chen R.; Xu L.; Fan Q.; Li M.; Wang J.; Wu L.; Li W.; Duan J.; Chen Z.; Hierarchical pulmonary target nanoparticles via inhaled administration for anticancer drug delivery. Drug Deliv  2017,24(1),1191-1203","journal-title":"Drug Deliv"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jconrel.2020.10.009","volume":"329","author":"Formiga F.R.","year":"2021","unstructured":"Formiga F.R.; Leblanc R.; de Souza Rebou\u00e7as J.; Farias L.P.; de Oliveira R.N.; Pena L.; Ivermectin: An award-winning drug with expected antiviral activity against COVID-19. J Control Release  2021,329,758-761","journal-title":"J Control Release"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"113953","DOI":"10.1016\/j.addr.2021.113953","volume":"177","author":"Garc\u00eda-Fern\u00e1ndez A.","year":"2021","unstructured":"Garc\u00eda-Fern\u00e1ndez A.; Sancen\u00f3n F.; Mart\u00ednez-M\u00e1\u00f1ez R.; Mesoporous silica nanoparticles for pulmonary drug delivery. Adv Drug Deliv Rev  2021,177,113953","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2174\/1567201817999200730211718","volume":"18","author":"Gencer A.","year":"2021","unstructured":"Gencer A.; Duraloglu C.; Ozbay S.; Ciftci T.T.; Yabanoglu-Ciftci S.; Arica B.; Recent advances in treatment of lung cancer: Nanoparticle-based drug and siRNA delivery systems. Curr Drug Deliv  2021,18(2),103-120","journal-title":"Curr Drug Deliv"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"101975","DOI":"10.1016\/j.pupt.2020.101975","volume":"64","author":"Gomez A.I.","year":"2020","unstructured":"Gomez A.I.; Acosta M.F.; Muralidharan P.; Yuan J.X.J.; Black S.M.; Hayes D.; Mansour H.M.; Advanced spray dried proliposomes of amphotericin B lung surfactant-mimic phospholipid microparticles\/nanoparticles as dry powder inhalers for targeted pulmonary drug delivery. Pulm Pharmacol Ther  2020,64,101975","journal-title":"Pulm Pharmacol Ther"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.xphs.2018.10.030","volume":"108","author":"Hamarat \u015eanl\u0131er \u015e.","year":"2019","unstructured":"Hamarat \u015eanl\u0131er \u015e.; Ak G.; Y\u0131lmaz H.; \u00dcnal A.; Bozkaya \u00dc.F.; Tan\u0131yan G.; Y\u0131ld\u0131r\u0131m Y.; Y\u0131ld\u0131z T\u00fcrky\u0131lmaz G.; Development of ultrasound-triggered and magnetic-targeted nanobubble system for dual-drug delivery. J Pharm Sci  2019,108(3),1272-1283","journal-title":"J Pharm Sci"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jconrel.2022.08.021","volume":"350","author":"Lazo R.E.L.","year":"2022","unstructured":"Lazo R.E.L.; Mengarda M.; Almeida S.L.; Caldonazo A.; Espinoza J.T.; Murakami F.S.; Advanced formulations and nanotechnology-based approaches for pulmonary delivery of sildenafil: A scoping review. J Control Release  2022,350,308-323","journal-title":"J Control Release"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/B978-0-08-102985-5.00023-1","author":"Bahmanpour A.H.","year":"2020","unstructured":"Bahmanpour A.H.; Nanotechnology for pulmonary and nasal drug delivery Nanoengineered Biomaterials for Advanced Drug Delivery  2020,561-579","journal-title":"Nanoengineered Biomaterials for Advanced Drug Delivery"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1080\/10717544.2022.2039809","volume":"29","author":"Yue P.","year":"2022","unstructured":"Yue P.; Zhou W.; Huang G.; Lei F.; Chen Y.; Ma Z.; Chen L.; Yang M.; Nanocrystals based pulmonary inhalation delivery system: Advance and challenge. Drug Deliv  2022,29(1),637-651","journal-title":"Drug Deliv"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jconrel.2020.07.011","volume":"326","author":"Shen A.M.","year":"2020","unstructured":"Shen A.M.; Minko T.; Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery. J Control Release  2020,326,222-244","journal-title":"J Control Release"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/978-1-0716-0319-2_10","volume":"2118","author":"Li H.Y.","year":"2020","unstructured":"Li H.Y.; Zhang F.; Preparation of spray-dried nanoparticles for efficient drug delivery to the lungs. Methods Mol Biol  2020,2118,139-145","journal-title":"Methods Mol Biol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s13346-018-0550-4","volume":"8","author":"Ngan C.L.","year":"2018","unstructured":"Ngan C.L.; Asmawi A.A.; Lipid-based pulmonary delivery system: A review and future considerations of formulation strategies and limitations. Drug Deliv Transl Res  2018,8(5),1527-1544","journal-title":"Drug Deliv Transl Res"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/03639045.2017.1391838","volume":"44","author":"Irvine J.","year":"2018","unstructured":"Irvine J.; Afrose A.; Islam N.; Formulation and delivery strategies of ibuprofen: challenges and opportunities. Drug Dev Ind Pharm  2018,44(2),173-183","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"109735","DOI":"10.1016\/j.cbi.2021.109735","volume":"351","author":"Subramaniyan V.","year":"2022","unstructured":"Subramaniyan V.; Fuloria S.; Gupta G.; Kumar D.H.; Sekar M.; Sathasivam K.V.; Sudhakar K.; Alharbi K.S.; Al-Malki W.H.; Afzal O.; Kazmi I.; Al-Abbasi F.A.; Altamimi A.S.A.; Fuloria N.K.; A review on epidermal growth factor receptor\u2019s role in breast and non-small cell lung cancer. Chem Biol Interact  2022,351,109735","journal-title":"Chem Biol Interact"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.3390\/nano11102557","volume":"11","author":"Sudhakar K.","year":"2021","unstructured":"Sudhakar K.; Fuloria S.; Subramaniyan V.; Sathasivam K.V.; Azad A.K.; Swain S.S.; Sekar M.; Karupiah S.; Porwal O.; Sahoo A.; Meenakshi D.U.; Sharma V.K.; Jain S.; Charyulu R.N.; Fuloria N.K.; Ultraflexible liposome nanocargo as a dermal and transdermal drug delivery system. Nanomaterials  2021,11(10),2557","journal-title":"Nanomaterials"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jconrel.2021.07.028","volume":"337","author":"Tammam S.N.","year":"2021","unstructured":"Tammam S.N.; El Safy S.; Ramadan S.; Arjune S.; Krakor E.; Mathur S.; Repurpose but also (nano)-reformulate! The potential role of nanomedicine in the battle against SARS-CoV2. J Control Release  2021,337,258-284","journal-title":"J Control Release"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.2174\/1389450115666140804124808","volume":"16","author":"Wolfram J.","year":"2015","unstructured":"Wolfram J.; Zhu M.; Yang Y.; Shen J.; Gentile E.; Paolino D.; Fresta M.; Nie G.; Chen C.; Shen H.; Ferrari M.; Zhao Y.; Safety of nanoparticles in medicine. Curr Drug Targets  2015,16(14),1671-1681","journal-title":"Curr Drug Targets"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jconrel.2022.09.021","volume":"351","author":"Zimmermann C.M.","year":"2022","unstructured":"Zimmermann C.M.; Baldassi D.; Chan K.; Adams N.B.P.; Neumann A.; Porras-Gonzalez D.L.; Wei X.; Kneidinger N.; Stoleriu M.G.; Burgstaller G.; Witzigmann D.; Luciani P.; Merkel O.M.; Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery. J Control Release  2022,351,137-150","journal-title":"J Control Release"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.03.017","volume":"392","author":"Pilcer G.","year":"2010","unstructured":"Pilcer G.; Amighi K.; Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm  2010,392(1-2),1-19","journal-title":"Int J Pharm"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"37","DOI":"10.15690\/vramn.v68i8.722","volume":"68","author":"Sanzhakov M.A.","year":"2013","unstructured":"Sanzhakov M.A.; Ipatova O.M.; Torkhovskaya T.I.; Prozorovski\u012d V.N.; Tikhonova E.G.; Druzhilovskaya O.S.; Medvedeva N.V.; [Nanoparticles as drug delivery system for antituberculous drugs]. Annals of the Russian academy of medical sciences  2013,68(8),37-44","journal-title":"Annals of the Russian academy of medical sciences"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1080\/10837450.2021.1950186","volume":"26","author":"Lombardo R.","year":"2021","unstructured":"Lombardo R.; Musumeci T.; Carbone C.; Pignatello R.; Nanotechnologies for intranasal drug delivery: An update of literature. Pharm Dev Technol  2021,26(8),824-845","journal-title":"Pharm Dev Technol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ejps.2016.05.012","volume":"92","author":"Muntimadugu E.","year":"2016","unstructured":"Muntimadugu E.; Dhommati R.; Jain A.; Challa V.G.S.; Shaheen M.; Khan W.; Intranasal delivery of nanoparticle encapsulated tarenflurbil: A potential brain targeting strategy for Alzheimer\u2019s disease. Eur J Pharm Sci  2016,92,224-234","journal-title":"Eur J Pharm Sci"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"6547","DOI":"10.2147\/IJN.S120939","volume":"11","author":"Bi C.","year":"2016","unstructured":"Bi C.; Wang A.; Chu Y.; Liu S.; Mu H.; Liu W.; Wu Z.; Sun K.; Li Y.; Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson\u2019s disease treatment. Int J Nanomedicine  2016,11,6547-6559","journal-title":"Int J Nanomedicine"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1019654","DOI":"10.3389\/fonc.2022.1019654","volume":"12","author":"Yun T.","year":"2022","unstructured":"Yun T.; Liu Z.; Wang J.; Wang R.; Zhu L.; Zhu Z.; Wang X.; Microenvironment immune response induced by tumor ferroptosis\u2014the application of nanomedicine. Front Oncol  2022,12,1019654","journal-title":"Front Oncol"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"105213","DOI":"10.1016\/j.ejps.2020.105213","volume":"144","author":"Zheng Y.","year":"2020","unstructured":"Zheng Y.; Li Z.; Chen H.; Gao Y.; Nanoparticle-based drug delivery systems for controllable photodynamic cancer therapy. Eur J Pharm Sci  2020,144,105213","journal-title":"Eur J Pharm Sci"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"7826","DOI":"10.7150\/thno.37216","volume":"9","author":"Zhuang J.","year":"2019","unstructured":"Zhuang J.; Holay M.; Park J.H.; Fang R.H.; Zhang J.; Zhang L.; Nanoparticle delivery of immunostimulatory agents for cancer immunotherapy. Theranostics  2019,9(25),7826-7848","journal-title":"Theranostics"},{"key":"ref=122","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1080\/21645515.2016.1183077","volume":"12","author":"Saleh T.","year":"2016","unstructured":"Saleh T.; Shojaosadati S.A.; Multifunctional nanoparticles for cancer immunotherapy. Hum Vaccin Immunother  2016,12(7),1863-1875","journal-title":"Hum Vaccin Immunother"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2174\/1574892817666220308090954","volume":"18","author":"Li H.","year":"2023","unstructured":"Li H.; Fu Q.; Muluh T.A.; Shinge S.A.U.; Fu S.; Wu J.; The application of nanotechnology in immunotherapy based combinations for cancer treatment. Recent Patents Anticancer Drug Discov  2023,18(1),53-65","journal-title":"Recent Patents Anticancer Drug Discov"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ijbiomac.2020.04.040","volume":"156","author":"Abd-Allah H.","year":"2020","unstructured":"Abd-Allah H.; Abdel-Aziz R.T.A.; Nasr M.; Chitosan nanoparticles making their way to clinical practice: A feasibility study on their topical use for acne treatment. Int J Biol Macromol  2020,156,262-270","journal-title":"Int J Biol Macromol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"113642","DOI":"10.1016\/j.jpba.2020.113642","volume":"192","author":"Fan Y.","year":"2021","unstructured":"Fan Y.; Marioli M.; Zhang K.; Analytical characterization of liposomes and other lipid nanoparticles for drug delivery. J Pharm Biomed Anal  2021,192,113642","journal-title":"J Pharm Biomed Anal"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.2174\/1389450121666200514222900","volume":"21","author":"Chen F.","year":"2020","unstructured":"Chen F.; Shi Y.; Zhang J.; Liu Q.; Nanoparticle-based drug delivery systems for targeted epigenetics cancer therapy. Curr Drug Targets  2020,21(11),1084-1098","journal-title":"Curr Drug Targets"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/bs.acr.2017.11.003","volume":"137","author":"Amreddy N.","year":"2018","unstructured":"Amreddy N.; Babu A.; Muralidharan R.; Panneerselvam J.; Srivastava A.; Ahmed R.; Mehta M.; Munshi A.; Ramesh R.; Recent advances in nanoparticle-based cancer drug and gene delivery. Adv Cancer Res  2018,137,115-170","journal-title":"Adv Cancer Res"}],"container-title":["Current Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115672018268047231207105652","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/226063\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115672018268047231207105652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T14:16:39Z","timestamp":1730470599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/226063\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":127,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115672018268047231207105652","relation":{},"ISSN":["1567-2018"],"issn-type":[{"value":"1567-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-08-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}